Kaiser Permanente, a major U.S. managed care consortium, reports that employer-sponsored health coverage for family premiums has increased by 113% since 2001 under the current system.1 Driven by the aging baby boomer generation as well as recent recession-related unemployment, Medicare and Medicaid enrollment is also dramatically increasing, straining state and federal budgets.2 In an attempt to ease budgetary pressures while increasing nationwide healthcare coverage, federal and state governments are acutely focused on reforming the current healthcare system. This provides an opportunity for AHM acceptance if proven to be a cost-effective adjunct or cheaper alternative to current therapies. Unfortunately, quantifying the true financial impact of AHM is challenging due to the scarcity of literature and the lack of standardized metrics across countries. One tool that is widely used in the U.K. and Canada, and could be beneficial if implemented in the U.S., is called the Quality-Adjusted Life Year (QALY). This metric considers both patient survival rates and quality of life gains to determine if a treatment is rational, recognizing that increased lifespan may not be incrementally valuable if the resulting quality of life is low. The measurement is not widely used in the U.S. for medical intervention therapy because the FDA does not take into account cost-effectiveness when determining drug approval. Given the present economic environment, the QALY could provide valuable data to